Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Galapagos NV is a biotechnology business based in the US. Galapagos shares (GLPG) are listed on the NASDAQ and all prices are listed in US Dollars. Galapagos employs 1,407 staff and has a market cap (total outstanding shares value) of USD$6.5 billion.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Casual investors
Latest market close | USD$118.12 |
---|---|
52-week range | USD$94.53 - USD$274.03 |
50-day moving average | USD$117.4403 |
200-day moving average | USD$152.3519 |
Wall St. target price | USD$118.52 |
PE ratio | 60.6469 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.686 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $118.12 from 2020-12-09
1 week (2021-01-12) | 15.18% |
---|---|
1 month (2020-12-22) | 20.62% |
3 months (2020-10-20) | -10.37% |
6 months (2020-07-20) | -44.69% |
1 year (2020-01-18) | N/A |
---|---|
2 years (2019-01-18) | 12.76% |
3 years (2018-01-19) | 5.05% |
5 years (2016-01-20) | 122.16% |
Valuing Galapagos stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Galapagos's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Galapagos's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, Galapagos shares trade at around 61x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Gross profit TTM | USD$468.6 million |
---|---|
Return on assets TTM | -2.01% |
Return on equity TTM | -13.84% |
Profit margin | -70.9% |
Book value | $25.493 |
Market capitalisation | USD$6.5 billion |
TTM: trailing 12 months
There are currently 964,153 Galapagos shares held short by investors – that's known as Galapagos's "short interest". This figure is 10.5% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Galapagos shares can be evaluated.
Galapagos's "short interest ratio" (SIR) is the quantity of Galapagos shares currently shorted divided by the average quantity of Galapagos shares traded daily (recently around 116584.40145103). Galapagos's SIR currently stands at 8.27. In other words for every 100,000 Galapagos shares traded daily on the market, roughly 8270 shares are currently held short.
However Galapagos's short interest can also be evaluated against the total number of Galapagos shares, or, against the total number of tradable Galapagos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galapagos's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Galapagos shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Galapagos shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Galapagos.
Find out more about how you can short Galapagos stock.
We're not expecting Galapagos to pay a dividend over the next 12 months.
Over the last 12 months, Galapagos's shares have ranged in value from as little as $94.53 up to $274.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galapagos's is 0.5401. This would suggest that Galapagos's shares are less volatile than average (for this exchange).
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.